ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
After being acquired by Pfizer for about $11.6 billion, Biohaven has relaunched as an independent company with assets Pfizer didn’t want. The deal gave Pfizer several migraine drugs and drug candidates, including Nurtec ODT and an intranasal spray to treat acute migraine. Pfizer owns about 3% of the new firm, which starts up with $258 million in cash. Its pipeline includes candidates for neurological and neuropsychiatric diseases.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X